» Articles » PMID: 33634529

Reactive Astrocytes As Treatment Targets in Alzheimer's Disease-Systematic Review of Studies Using the APPswePS1dE9 Mouse Model

Overview
Journal Glia
Specialty Neurology
Date 2021 Feb 26
PMID 33634529
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Astrocytes regulate synaptic communication and are essential for proper brain functioning. In Alzheimer's disease (AD) astrocytes become reactive, which is characterized by an increased expression of intermediate filament proteins and cellular hypertrophy. Reactive astrocytes are found in close association with amyloid-beta (Aβ) deposits. Synaptic communication and neuronal network function could be directly modulated by reactive astrocytes, potentially contributing to cognitive decline in AD. In this review, we focus on reactive astrocytes as treatment targets in AD in the APPswePS1dE9 AD mouse model, a widely used model to study amyloidosis and gliosis. We first give an overview of the model; that is, how it was generated, which cells express the transgenes, and the effect of its genetic background on Aβ pathology. Subsequently, to determine whether modifying reactive astrocytes in AD could influence pathogenesis and cognition, we review studies using this mouse model in which interventions were directly targeted at reactive astrocytes or had an indirect effect on reactive astrocytes. Overall, studies specifically targeting astrocytes to reduce astrogliosis showed beneficial effects on cognition, which indicates that targeting astrocytes should be included in developing novel therapies for AD.

Citing Articles

Stereo-seq of the prefrontal cortex in aging and Alzheimer's disease.

Gong Y, Haeri M, Zhang X, Li Y, Liu A, Wu D Nat Commun. 2025; 16(1):482.

PMID: 39779708 PMC: 11711495. DOI: 10.1038/s41467-024-54715-y.


Zinc signaling controls astrocyte-dependent synapse modulation via the PAF receptor pathway.

Stanton J, Hans S, Zabetakis I, Grabrucker A J Neurochem. 2024; 169(2):e16252.

PMID: 39450676 PMC: 11808829. DOI: 10.1111/jnc.16252.


Integrative approach of omics and imaging data to discover new insights for understanding brain diseases.

Yoon J, Lee H, Kwon D, Lee D, Lee S, Cho E Brain Commun. 2024; 6(4):fcae265.

PMID: 39165479 PMC: 11334939. DOI: 10.1093/braincomms/fcae265.


Spatial Dissection of the Distinct Cellular Responses to Normal Aging and Alzheimer's Disease in Human Prefrontal Cortex at Single-Nucleus Resolution.

Gong Y, Haeri M, Zhang X, Li Y, Liu A, Wu D medRxiv. 2024; .

PMID: 38826275 PMC: 11142279. DOI: 10.1101/2024.05.21.24306783.


Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease.

Huang Y, Wang M, Ni H, Zhang J, Li A, Hu B Nat Neurosci. 2024; 27(8):1489-1504.

PMID: 38802590 PMC: 11346591. DOI: 10.1038/s41593-024-01664-w.


References
1.
Hyman B, Tanzi R . Effects of Species-Specific Genetics on Alzheimer's Mouse Models. Neuron. 2019; 101(3):351-352. DOI: 10.1016/j.neuron.2019.01.021. View

2.
Qu B, Xiang Q, Li L, Johnston S, Hynan L, Rosenberg R . Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. J Neurol Sci. 2007; 260(1-2):204-13. PMC: 2587214. DOI: 10.1016/j.jns.2007.05.012. View

3.
Mori T, Rezai-Zadeh K, Koyama N, Arendash G, Yamaguchi H, Kakuda N . Tannic acid is a natural β-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem. 2012; 287(9):6912-27. PMC: 3307267. DOI: 10.1074/jbc.M111.294025. View

4.
Ben Haim L, Ceyzeriat K, Carrillo-de Sauvage M, Aubry F, Auregan G, Guillermier M . The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. J Neurosci. 2015; 35(6):2817-29. PMC: 6605603. DOI: 10.1523/JNEUROSCI.3516-14.2015. View

5.
Wakabayashi T, De Strooper B . Presenilins: members of the gamma-secretase quartets, but part-time soloists too. Physiology (Bethesda). 2008; 23:194-204. DOI: 10.1152/physiol.00009.2008. View